- Home
- RVT vs EWTX Comparison
RVT vs EWTX Comparison
Compare RVT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- EWTX
- Stock Information
- Founded
- RVT 1986
- EWTX 2017
- Country
- RVT United States
- EWTX United States
- Employees
- RVT N/A
- EWTX N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- EWTX Health Care
- Exchange
- RVT Nasdaq
- EWTX Nasdaq
- Market Cap
- RVT 1.9B
- EWTX 1.6B
- IPO Year
- RVT N/A
- EWTX 2021
- Fundamental
- Price
- RVT N/A
- EWTX $15.70
- Analyst Decision
- RVT
- EWTX Buy
- Analyst Count
- RVT 0
- EWTX 10
- Target Price
- RVT N/A
- EWTX $37.90
- AVG Volume (30 Days)
- RVT 243.4K
- EWTX 974.3K
- Earning Date
- RVT 01-01-0001
- EWTX 11-06-2025
- Dividend Yield
- RVT 7.32%
- EWTX N/A
- EPS Growth
- RVT N/A
- EWTX N/A
- EPS
- RVT 2.95
- EWTX N/A
- Revenue
- RVT N/A
- EWTX N/A
- Revenue This Year
- RVT N/A
- EWTX N/A
- Revenue Next Year
- RVT N/A
- EWTX N/A
- P/E Ratio
- RVT $4.98
- EWTX N/A
- Revenue Growth
- RVT N/A
- EWTX N/A
- 52 Week Low
- RVT $11.85
- EWTX $10.60
- 52 Week High
- RVT $14.93
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- RVT 57.99
- EWTX 51.91
- Support Level
- RVT $16.20
- EWTX $14.94
- Resistance Level
- RVT $16.48
- EWTX $15.84
- Average True Range (ATR)
- RVT 0.19
- EWTX 0.98
- MACD
- RVT -0.02
- EWTX -0.06
- Stochastic Oscillator
- RVT 59.26
- EWTX 42.70
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.